|
EP1455826A2
|
|
Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment of multiple sclerosis
|
|
WO0168076A2
|
|
D-enantiomer of dfmo and methods of use thereof for treating cancer
|
|
US2002045663A1
|
|
D-enantiomer of DFMO and methods of use therefor
|
|
US6589981B2
|
|
Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
|
|
WO0069434A1
|
|
Dfmo and celecoxib in combination for cancer chemoprevention and therapy
|
|
AU5526898A
|
|
Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer
|
|
CA2241896A1
|
|
Sustained release formulation containing dfmo
|
|
WO9814188A1
|
|
Dfmo and taxol for the treatment or prevention of breast cancer
|
|
AU4046197A
|
|
Use of 5,6-dihydro-5-azacytidine in the treatment of prostate cancer
|
